Conditions: Metastatic Colorectal Cancer
Keywords: Colorectal Cancer Cediranib RECENTIN
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1254
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine if Cediranib when added to chemotherapy is more effective than chemotherapy alone in prolonging life expectancy and slowing disease progression in patients with previously untreated metastatic colorectal cancer.

Detailed description:

Arms:
arm 1: FOLFOX + placebo Cediranib arm 2: Xelox + placebo Cediranib arm 3: FOLFOX + Cediranib arm 4: XELOX + Cediranib

Interventions: intervention 1: Cediranib intervention 2: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) intervention 3: XELOX (Capecitabine and Oxaliplatin) intervention 4: Cediranib Placebo
Intervention descriptions: intervention 1: oral tablet intervention 2: intravenous infusion intervention 3: intravenous oxaliplatin 130 mg/ m\^2(day 1) followed by oral capecitabine 1,000 mg/ m\^2twice daily (day 1 to day 15) intervention 4: oral tablet

Protocol document: